SMT Supraflex Cruz Stent Approved in Canada
Analysis based on 6 articles · First reported Sep 09, 2026 · Last updated Sep 09, 2026
The approval enables SMT to sell its coronary stent in Canada, potentially increasing revenue and market share in North America. As SMT is pre-IPO, this regulatory milestone may positively influence investor sentiment ahead of its planned public offering.
Sahajanand Medical Technologies Limited (SMT) received a Class IV medical device license from Canada — Health Canada's Medical Devices Directorate for its Supraflex Cruz sirolimus-eluting coronary stent system. This approval allows the device to be imported and sold in Canada, marking SMT's entry into the Canadian market. The license covers the Supraflex Sirolimus Eluting Stent System family and lists Supraflex Cruz as a licensed device. This approval is part of SMT's strategy to expand international availability of its coronary-intervention technologies. The company is also preparing for an initial public offering in India, having filed a draft red herring prospectus with SEBI.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard